Cancer Center Misconduct Case Raises Thorny Issues

Cases of potential scientific misconduct are rarely routine, and even those that seem to have the potential for a swift conclusion often metamorphose into highly contentious and confused proceedings. A recent case involving Philadelphia's Fox Chase Cancer Center (FCCC) illustrates some of the difficulties institutions face in responding to misconduct allegations-especially with regard to conflicts that arise when institutions must police themselves. THE FIRST TIME: Fox Chase president Robert

Written byBilly Goodman
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

Cases of potential scientific misconduct are rarely routine, and even those that seem to have the potential for a swift conclusion often metamorphose into highly contentious and confused proceedings. A recent case involving Philadelphia's Fox Chase Cancer Center (FCCC) illustrates some of the difficulties institutions face in responding to misconduct allegations-especially with regard to conflicts that arise when institutions must police themselves.

THE FIRST TIME: Fox Chase president Robert Young notes that "This was the first [misconduct case] we've ever dealt with." In this case, a technician was alleged to have falsified research data in a May 1993 experiment to measure the impact that switching solvents had on the rate of a reaction catalyzed by the enzyme fumarase. A whistleblower raised her concerns to Fox Chase and the Public Health Service's Office of Research Integrity (ORI) in 1994. ORI has oversight in the case because PHS funds were used in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies